AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02696109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
Study NCT02696109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cornerstone
Description: Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
Study NCT00438048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pilocarpine
Description: or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
Study NCT00438048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Saliva
Description: 5ml 3 times daily
Study NCT02182362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03463564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
Study NCT03463564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin injections
Description: Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
Study NCT01816828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gay Poz Sex
Description: Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
Study NCT01816828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait List/Standard of Care
Description: Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
Study NCT00177970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin G (IVIG)
Description: IVIG to be given IV to patients with C-Diff .
Study NCT00177970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given IV to patients with C-Diff
Study NCT04523233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Amniocentesis
Description: Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
Study NCT02149173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo F-18 FES PET/CT
Study NCT02149173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT02149173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Undergo F-18 FES PET/CT
Study NCT02149173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT02149173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02149173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo F-18 FES PET/CT
Study NCT02149173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT02858219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT02858219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study NCT02858219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indexes
Description: Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
Study NCT02858219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Indexes
Description: Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
Study NCT01463371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250 mg three times a week during three months
Study NCT02467556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine, memantine
Description: Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
Study NCT02467556 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological intervention
Description: To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
Study NCT02467556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy intervention
Description: Graded motor imagenary with group and individual weekly sessions with daily practices at home.
Study NCT00634088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
Description: Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
Study NCT00634088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
Description: Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
Study NCT00634088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
Description: Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
Study NCT00634088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone + Lapatinib + Capecitabine
Description: Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
Study NCT03689166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Reduce preterm birth with this dietary supplement
Study NCT03689166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02592746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
Study NCT02592746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg, orally once daily
Study NCT02592746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide Acetate 3.75mg SC q 4weeks
Study NCT02592746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
Study NCT03000699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
Study NCT01238614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA PSF plus JIT
Study NCT01238614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA maternal depression PSF
Study NCT01238614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01389180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and HIV Risk Reduction Counseling
Description: BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
Study NCT01389180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Counseling
Description: EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
Study NCT01389180 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
Study NCT04361162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study NCT04361162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
Study NCT04361162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 3D Conformal Radiotherapy to shrink or kill tumors
Study NCT01936935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Description: 2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
Study NCT01936935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar-sweetened beverages
Description: 2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
Study NCT04176276 — intervention group
Intervention type: OTHER
Intervention: no interventions required.
Description: The study does not require any interventions.
Study NCT00149409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omacor
Study NCT00211692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: consensus interferon (Interferon Alfacon-1) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
Study NCT00211692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consensus Interferon alfa (CIFN) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
Study NCT00211692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consensus Interferon alfa (CIFN) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
Study NCT03017066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
Study NCT03017066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Scheduled operation under general anesthesia
Study NCT04309175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: base rate programming of a permanent cardiac pacemaker
Description: Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
Study NCT00149409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omacor
Study NCT02918045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing
Description: The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
Study NCT02918045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidized Cellulose Gauze
Description: A common hemostatic measure after dental extractions placed into the extraction socket.
Study NCT03060525 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Deaf Weight Wise 2.0
Description: Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase.
Study NCT03060525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deaf Weight Wise 2.0
Description: Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase.
Study NCT01990183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareToy
Description: Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
Study NCT01990183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Current care advices in the management of preterm infants in the first months of life
Study NCT01272349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia
Description: 30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
Study NCT01272349 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: 30 minutes of breathing room air followed by walking on a body-weight support treadmill
Study NCT01590056 — intervention group
Intervention type: OTHER
Intervention: Electrophysiological recording
Description: During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test
Study NCT00158275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
Study NCT00158275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
Study NCT00158275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
Study NCT03471494 — intervention group
Intervention type: OTHER
Intervention: Exposure: human development index of country
Description: Primary comparison: Between country groups defined by human development index.
Study NCT03650387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADIESSE® (+) Lidocaine
Description: RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
Study NCT03596684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose tolerance test
Description: 2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
Study NCT04306081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
Study NCT00646399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
Study NCT01227941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827 + pegylated liposomal doxorubicin
Description: Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
Study NCT00646399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab 50 mg/mL
Description: Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23